Drilling Down Into Akers Biosciences, Inc. (AKER)

Akers Biosciences, Inc. (AKER) is an interesting player in the Healthcare space, with a focus on Medical Instruments & Supplies. The stock has been active on the tape, currently trading at $0.41, down from yesterday’s close by -5.27%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

Akers Biosciences, Inc. (AKER) currently trades with a market capitalization of $24.75 Million. That value represents a market adjusting for revenues that have been growing by 10.21 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of -$3.69 Million over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $0.06 on a per share basis this quarter. Perhaps, that suggests something about why 2.73% of the outstanding share supply is held by institutional investors.

Technical Analysis

No analysis is ever complete without a thorough survey of a stock’s technical behavior. Looking at the stock’s movement on the chart, Akers Biosciences, Inc. recorded a 52-week high of $2.90. It is now trading 2.49% off that level. The stock is trading $0.29 its 50-day moving average by -0.12%. The stock carved out a 52-week low down at $0.12.

In recent action, Akers Biosciences, Inc. (AKER) has made a move of +127.78% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 12.51, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 17.42% with $53.32 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of AKER.

Previous articleGuess’, Inc. (GES): From Top to Bottom
Next articleJust the Facts on BioPharmX Corporation (BPMX)